[Initial treatment of venous thromboembolic events].

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52

Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64

Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest (2007) 2.32

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21

Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology (2006) 2.18

Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09

Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84

Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. Thromb Res (2008) 1.41

Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study. Blood (2013) 1.39

Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost (2003) 1.29

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost (2009) 0.94

Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost (2003) 0.92

Intravenous thrombolytic therapy in patients with phlegmasia caerulea dolens. Haematologica (2006) 0.89

Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res (2007) 0.81

Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest (2005) 0.79

The risk of subsequent cancer and arterial cardiovascular events in patients with superficial vein thrombosis in the legs. Blood (2011) 0.79

Recent findings in the epidemiology, diagnosis and treatment of superficial-vein thrombosis. Thromb Res (2011) 0.79

The cloud of pulmonary embolism during COPD exacerbation. Thorax (2011) 0.78

Splice variant-specific stabilization of JNKs by IB1/JIP1. Cell Signal (2007) 0.78

Role of fibrinolysis and interventional therapy for acute venous thromboembolism. Thromb Haemost (2006) 0.76

Thrombosis prophylaxis in cancer patients with a central venous catheter. Arch Intern Med (2004) 0.75

[New oral anticoagulants in the treatment of venous thromboembolism]. Presse Med (2013) 0.75

The location of deep-vein thrombosis as a predictive factor for recurrence and cancer discovery after proximal deep-vein thrombosis. Haematologica (2003) 0.75

Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis. Future Cardiol (2005) 0.75

[Management of superficial vein thrombosis]. Rev Prat (2015) 0.75

[Epidemiologic and therapeutic advances in superficial venous thrombosis of the legs]. Rev Prat (2011) 0.75

Lessons learned from cancer/VTE Registries: report from RIETE. Thromb Res (2007) 0.75